ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
0,00%
Bitcoin
63.788,23
-0,16%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Better Therapeutics Inc (BTTX)

  7. Better Therapeutics Inc (BTTX) News

BTTX

Better Therapeutics (BTTX)

Better Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BTTX
DatumZeitQuelleÜberschriftSymbolFirma
14/03/202414h38Business WireBetter Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from NasdaqNASDAQ:BTTXBetter Therapeutics Inc
11/03/202414h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTTXBetter Therapeutics Inc
05/03/202415h25Business WireBetter Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health CentersNASDAQ:BTTXBetter Therapeutics Inc
04/03/202415h25Business WireBetter Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)NASDAQ:BTTXBetter Therapeutics Inc
04/03/202414h51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTTXBetter Therapeutics Inc
01/03/202412h08Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:BTTXBetter Therapeutics Inc
20/02/202415h25Business WireBetter Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver DiseaseNASDAQ:BTTXBetter Therapeutics Inc
12/02/202422h28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BTTXBetter Therapeutics Inc
06/02/202415h43Business WireBetter Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes TreatmentNASDAQ:BTTXBetter Therapeutics Inc
06/02/202415h02Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:BTTXBetter Therapeutics Inc
25/01/202422h30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BTTXBetter Therapeutics Inc
23/01/202423h22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:BTTXBetter Therapeutics Inc
17/01/202415h28Business WireBetter Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care AloneNASDAQ:BTTXBetter Therapeutics Inc
10/01/202413h01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BTTXBetter Therapeutics Inc
08/01/202422h42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTTXBetter Therapeutics Inc
04/01/202420h00Business WireBetter Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United StatesNASDAQ:BTTXBetter Therapeutics Inc
02/01/202413h45Business WireBetter Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver DiseaseNASDAQ:BTTXBetter Therapeutics Inc
29/12/202303h23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BTTXBetter Therapeutics Inc
28/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BTTXBetter Therapeutics Inc
21/12/202323h21Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:BTTXBetter Therapeutics Inc
20/12/202323h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTTXBetter Therapeutics Inc
20/12/202323h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTTXBetter Therapeutics Inc
20/12/202323h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTTXBetter Therapeutics Inc
13/12/202323h24Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:BTTXBetter Therapeutics Inc
13/12/202323h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTTXBetter Therapeutics Inc
08/12/202302h09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BTTXBetter Therapeutics Inc
30/11/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTTXBetter Therapeutics Inc
28/11/202313h45Business WireBetter Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost ReductionsNASDAQ:BTTXBetter Therapeutics Inc
20/11/202323h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTTXBetter Therapeutics Inc
14/11/202313h00Business WireFrost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership AwardNASDAQ:BTTXBetter Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BTTX

Kürzlich von Ihnen besucht

CCOM
US30
US 30
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
XOM
Exxon Mobil
CCOM
US500
US 500
NYSE
MRK
Merck
DBI
TDXP
Tec DAX
CCOM
SILVER
SILVER
AMEX
XLE
Energy Select Sector SPDR
DBI
SDXP
SDAX
TG
NOV
Novo Nordisk
FX
EURGBP
Euro vs Sterling
USOTC
ADDYY
Adidas (QX)
NASDAQ
TSLA
Tesla
TG
MBG
MercedesBenz
TG
RHM
Rheinmetall
TG
TUI1
Tui
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten